Author
Listed:
- Dasom Shin
(Seoul National University Hospital
Seoul National University Hospital
Seoul National University)
- Soungchan Kim
(Seoul National University Hospital
Seoul National University Hospital
Seoul National University)
- Hwan Lee
(Seoul National University Hospital
Seoul National University Hospital
Seoul National University)
- Hyun-Chae Lee
(Seoul National University Hospital
Seoul National University Hospital)
- Jaewon Lee
(Seoul National University Hospital
Seoul National University Hospital)
- Hyun-woo Park
(Seoul National University Hospital
Seoul National University Hospital
Seoul National University College of Medicine)
- Mina Fukai
(Seoul National University Hospital
Seoul National University Hospital
Seoul National University)
- EunByule Choi
(Seoul National University Hospital
Seoul National University Hospital
Seoul National University)
- Subin Choi
(Seoul National University Hospital
Seoul National University Hospital
Seoul National University)
- Bon-Jun Koo
(Seoul National University Hospital
Seoul National University Hospital
Seoul National University)
- Ji-Hoon Yu
(Seoul National University Hospital
Seoul National University Hospital
Seoul National University)
- Gyurae No
(Seoul National University Hospital
Seoul National University Hospital
Seoul National University)
- Sungyoon Cho
(Seoul National University Hospital
Seoul National University Hospital
Seoul National University College of Medicine)
- Chan Woo Kim
(Laboratory Animal Center, Osong Medical Innovation Foundation (KBIO))
- Dohyun Han
(Seoul National University Hospital)
- Hyun-Duk Jang
(Seoul National University Hospital
Seoul National University Hospital)
- Hyo-Soo Kim
(Seoul National University Hospital
Seoul National University
Seoul National University College of Medicine
Seoul National University Hospital)
Abstract
Proprotein convertase subtilisin/kexin type-9 (PCSK9) binds to and degrades low-density lipoprotein (LDL) receptor, leading to increase of LDL cholesterol in blood. Its blockers have emerged as promising therapeutics for cardiovascular diseases. Here we show that PCSK9 itself directly induces inflammation and aggravates atherosclerosis independently of the LDL receptor. PCSK9 exacerbates atherosclerosis in LDL receptor knockout mice. Adenylyl cyclase-associated protein 1 (CAP1) is the main binding partner of PCSK9 and indispensable for the inflammatory action of PCSK9, including induction of cytokines, Toll like receptor 4, and scavenger receptors, enhancing the uptake of oxidized LDL. We find spleen tyrosine kinase (Syk) and protein kinase C delta (PKCδ) to be the key mediators of inflammation after PCSK9-CAP1 binding. In human peripheral blood mononuclear cells, serum PCSK9 levels are positively correlated with Syk, PKCδ, and p65 phosphorylation. The CAP1-fragment crystallizable region (CAP1-Fc) mitigates PCSK9-mediated inflammatory signal transduction more than the PCSK9 blocking antibody evolocumab does.
Suggested Citation
Dasom Shin & Soungchan Kim & Hwan Lee & Hyun-Chae Lee & Jaewon Lee & Hyun-woo Park & Mina Fukai & EunByule Choi & Subin Choi & Bon-Jun Koo & Ji-Hoon Yu & Gyurae No & Sungyoon Cho & Chan Woo Kim & Dohy, 2024.
"PCSK9 stimulates Syk, PKCδ, and NF-κB, leading to atherosclerosis progression independently of LDL receptor,"
Nature Communications, Nature, vol. 15(1), pages 1-22, December.
Handle:
RePEc:nat:natcom:v:15:y:2024:i:1:d:10.1038_s41467-024-46336-2
DOI: 10.1038/s41467-024-46336-2
Download full text from publisher
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:15:y:2024:i:1:d:10.1038_s41467-024-46336-2. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.